Alexza Pharmaceuticals Inc (ALXA) Financial Statements (2024 and earlier)

Company Profile

Business Address 2091 STIERLIN COURT
MOUNTAIN VIEW, CA 94043
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,75511,28715,69622,52034,77434,887
Cash and cash equivalents7,75511,28712,19311,09315,20011,626
Short-term investments   3,50311,42719,57423,261
Receivables 822303991731,008
Inventory, net of allowances, customer advances and progress billings  1031,4072,4723,7294,414
Inventory  1031,4072,4723,7294,414
Advances on inventory purchases 1,0241,0241,0241,024  
Other undisclosed current assets2,2131885411,1453,1093,039
Total current assets:10,99213,42418,97127,26041,78543,348
Noncurrent Assets
Property, plant and equipment3,32010,30111,01411,69313,95315,017
Restricted cash and investments    1,3612,7574,160
Other noncurrent assets4192,4972,6482,8563,0653,272
Total noncurrent assets:3,73912,79813,66215,91019,77522,449
TOTAL ASSETS:14,73126,22232,63343,17061,56065,797
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,4326,6175,4494,67810,4176,461
Employee-related liabilities     2,781 
Accounts payable4429052,6181,5651,7991,692
Accrued liabilities6,9905,7122,8313,1135,8374,769
Debt46,8402,914 64,15763,76763,579
Business combination, contingent consideration, liability9008009008001,7001,400
Deferred revenue and credits2,8482,8482,9702,4502,4502,374
Other undisclosed current liabilities178134689(63,844)(66,817)(62,821)
Total current liabilities:58,19813,31310,0088,24111,51710,993
Noncurrent Liabilities
Long-term debt and lease obligation, including:21,12767,68864,53064,15763,76763,378
Long-term debt, excluding current maturities21,12764,77464,53064,15763,76763,378
Other undisclosed long-term debt and lease obligation  2,914    
Liabilities, other than long-term debt7,06416,98422,00522,43937,92940,265
Deferred revenue and credits3,4124,4715,5306,9027,8447,336
Other liabilities 1,7521,6131,4751,237985729
Business combination, contingent consideration, liability1,90010,90015,00014,30029,10032,200
Total noncurrent liabilities:28,19184,67286,53586,596101,696103,643
Total liabilities:86,38997,98596,54394,837113,213114,636
Equity
Equity, attributable to parent(71,658)(68,849)(63,910)(51,667)(51,653)(48,839)
Common stock222222
Additional paid in capital360,610360,401359,902359,696359,308355,413
Accumulated other comprehensive loss    (1)(3)(1)
Accumulated deficit(432,270)(429,252)(423,814)(411,364)(410,960)(404,253)
Total equity:(71,658)(68,849)(63,910)(51,667)(51,653)(48,839)
Other undisclosed liabilities and equity  (2,914)    
TOTAL LIABILITIES AND EQUITY:14,73126,22232,63343,17061,56065,797

Income Statement (P&L) ($ in thousands)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
Revenues6731,7731,8757051,454457
Revenue, net 1,7731,875618536364
Cost of revenue
(Cost of Goods and Services Sold)
(7,175)(3,675)(4,132)(6,147)(3,952)(3,279)
Gross profit:(6,502)(1,902)(2,257)(5,442)(2,498)(2,822)
Operating expenses(2,100)(5,695)(7,184)(8,942)(4,774)(7,218)
Other undisclosed operating income (loss) (1,381)  1,3818 
Operating loss:(9,983)(7,597)(9,441)(13,003)(7,264)(10,040)
Interest and debt expense(2,050)(1,969)(2,198)(2,229)(2,234)(2,202)
Other undisclosed income from continuing operations before equity method investments, income taxes     1,032 
Loss from continuing operations:(12,033)(9,566)(11,639)(15,232)(8,466)(12,242)
Loss before gain (loss) on sale of properties:(12,033)(9,566)(11,639)(15,232)(8,466)(12,242)
Net loss:(12,033)(9,566)(11,639)(15,232)(8,466)(12,242)
Other undisclosed net income (loss) attributable to parent9,0154,128(811)14,8281,759(1,086)
Net loss available to common stockholders, diluted:(3,018)(5,438)(12,450)(404)(6,707)(13,328)

Comprehensive Income ($ in thousands)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
Net loss:(12,033)(9,566)(11,639)(15,232)(8,466)(12,242)
Other comprehensive loss   (12,449)(402)(6,709)(13,331)
Comprehensive loss:(12,033)(9,566)(24,088)(15,634)(15,175)(25,573)
Other undisclosed comprehensive income, net of tax, attributable to parent9,0184,125    
Comprehensive loss, net of tax, attributable to parent:(3,015)(5,441)(24,088)(15,634)(15,175)(25,573)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: